Hikma Pharmaceuticals Plc Holding(s) in Company (8170O)
February 11 2016 - 7:43AM
UK Regulatory
TIDMHIK
RNS Number : 8170O
Hikma Pharmaceuticals Plc
11 February 2016
Notification of major interests in shares
LONDON, 11 February 2016 - Hikma Pharmaceuticals PLC ("Hikma")
(LSE: HIK) (DIFX: HIK), the fast growing multinational
pharmaceuticals group, announces as follows:
1 Identity of the issuer or the Hikma Pharmaceuticals
underlying issuer of existing PLC
shares to which the voting
rights are attached
------------------------------- ----------------------
2 Reason for the notification
------------------------------------------ ----
An acquisition or disposal of voting Yes
rights
------------------------------------------ ----
An acquisition or disposal of financial No
instruments which may result in the
acquisition of shares already issues
to which voting rights are attached
------------------------------------------ ----
An event changing the breakdown of voting No
rights
------------------------------------------ ----
Other (please specify): Compliance with No
the Transparency Directive
------------------------------------------ ----
3 Full name of the person subject Vanguard Healthcare Fund
to the notification obligation
-------------- ------------------------------------------ -----------------------------------------
4 Full name of shareholders Vanguard Healthcare Fund
-------------- ------------------------------------------ -----------------------------------------
5 Date of the Transaction (and 8 February 2016
date on which the threshold
crossed is reached differently)
-------------- ------------------------------------------ -----------------------------------------
6 Date on which the issuer notified 10 February 2016
-------------- ------------------------------------------ -----------------------------------------
7 Threshold that is crossed 3%
-------------- ------------------------------------------ -----------------------------------------
8 Notified details See A, B & C below
-------------- ------------------------------------------ -----------------------------------------
A. Voting rights attached to shares
-----------------------------------------------------------------------------------------------------
Class type Situation previous Resulting situation after the
of shares to the triggering triggering transaction
(if possible transaction
using the
ISIN code)
---------------- ------------------------- --------------------------------------------------------
Number Number Number Number of voting % of voting
of shares of voting of shares rights rights
rights
-------------- ------------ ----------- ----------- ----------------------- ------------------
Direct Direct Indirect Direct Indirect
-------------- ------------ ----------- ----------- ------------ --------- ------- ---------
Ordinary
Shares
(0.10 GBP)
GB00B0LCW083 5,912,554 5,912,554 6,008,846 6,008,846 3.01%
---------------- ------------ ----------- ----------- ------------ --------- ------- ---------
B. Qualifying Financial instruments
---------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
---------------------------------------------------------------------------------------
Type of Expiration Exercise/Conversion Number of % of voting
financial Date Period/Date voting rights rights
instrument that may be
acquired if
the instrument
if exercised/converted
------------ ----------- -------------------- ------------------------ ------------
- - - - -
------------ ----------- -------------------- ------------------------ ------------
C: Financial Instruments with similar economic effect
to Qualifying Financial Instruments
---------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
---------------------------------------------------------------------------------------------
Type of Exercise Expiration Exercise/Conversion Number of % of voting
financial Price Date Period/Date voting rights rights
instrument instrument
refers to
------------ --------- ----------- -------------------- --------------- ----------------
Nominal Delta
------------ --------- ----------- -------------------- --------------- -------- ------
- - - - - - -
------------ --------- ----------- -------------------- --------------- -------- ------
Total A+B+C
---------------------------------------------
Number of Voting rights % of voting rights
------------------------ -------------------
6,008,846 3.01
------------------------ -------------------
9 Chain of controlled undertakings through which
the voting rights and/or the financial instruments
are effectively held, if applicable
----------------------------------------------------
N/A
----------------------------------------------------
Proxy Voting
-----------------------------------------
10 Name of the proxy holder N/A
--- ------------------------------ ----
11 Number of voting rights proxy
holder will cease to hold:
--- ------------------------------ ----
12 Date on which proxy holder
will cease to hold voting
rights:
--- ------------------------------ ----
13 Additional Information
--- -------------------------- ---------------------------------------
14 Contact name: Vanguard Health Care
Fund
c/o The Vanguard Group,
Inc.
Vanguard_Fund_Compliance@Vanguard.com
--- -------------------------- ---------------------------------------
15 Contact telephone number: +001 (610) 669-8989
--- -------------------------- ---------------------------------------
- ENDS -
About Hikma
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group
focused on developing, manufacturing and marketing a broad range of
both branded and non-branded generic and in-licensed products.
Hikma's operations are conducted through three businesses:
"Branded", "Injectables" and "Generics" based primarily in the
Middle East and North Africa ("MENA") region, where it is a market
leader, the United States and Europe. In 2014, Hikma achieved
revenues of $1,489 million and profit attributable to shareholders
of $278 million.
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLUASURNUAUAAR
(END) Dow Jones Newswires
February 11, 2016 07:43 ET (12:43 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024
